Antiatherogenic small, dense HDL - Guardian angel of the arterial wall?

Nature Clinical Practice Cardiovascular Medicine

Volumn 3, Issue 3, 2006, Pages 144-153

  Kontush, Anatol ^a   Chapman, M John ^a  

^a INSERM   (France)

Author keywords

Cardiovascular disease; HDL; Inflamation; Oxidative stress; Small dense HDL

Indexed keywords

2 METHYLPROPANETHIOIC ACID S [2 [1 (2 ETHYLBUTYL)CYCLOHEXYLCARBOXAMIDO]PHENYL] ESTER; AMYLOID A PROTEIN; APOLIPOPROTEIN A1; CHOLESTEROL ESTER; CHOLESTEROL ESTER TRANSFER PROTEIN INHIBITOR; FIBRIC ACID DERIVATIVE; GEMFIBROZIL; HIGH DENSITY LIPOPROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; NICOTINIC ACID; PHOSPHOLIPID; SIMVASTATIN; TORCETRAPIB; TRIACYLGLYCEROL;

ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; ARTERY WALL; ATHEROSCLEROSIS; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; DRUG MECHANISM; DRUG POTENTIATION; DYSLIPIDEMIA; HUMAN; LIPID COMPOSITION; LIPOPROTEIN METABOLISM; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; PARTICULATE MATTER; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; REVIEW; TRIACYLGLYCEROL BLOOD LEVEL;

ANTILIPEMIC AGENTS; BIOLOGICAL MARKERS; CARDIOVASCULAR DISEASES; CHOLESTEROL, HDL; DYSLIPIDEMIAS; HUMANS; LIPOPROTEINS, HDL; LIPOPROTEINS, HDL3;

EID: 33644608784     PISSN: 17434297     EISSN: None     Source Type: Journal    
DOI: 10.1038/ncpcardio0500     Document Type: Review

References (60)

1. Chapman MJ et al. (2004) Raising high-density lipoprotein cholesterol with reduction of cardiovascular risk: The role of nicotinic acid - a position paper developed by the European Consensus Panel on HDL-C. Curr Med Res Opin 20: 1253-1268
2. Lusis AJ (2000) Atherosclerosis. Nature 407: 233-241
3. Verma S et al. (2005) C-reactive protein comes of age. Nature Clin Pract Cardiovasc Med 2: 29-36
4. Hansson GK (2005) Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med 352: 1685-1695
5. Gaut JP and Heinecke JW (2001) Mechanisms for oxidizing low-density lipoprotein: Insights from patterns of oxidation products in the artery wall and from mouse models of atherosclerosis. Trends Cardiovasc Med 11: 103-112
6. Barter P et al. (2003) High density lipoproteins (HDLs) and atherosclerosis; the unanswered questions. Atherosclerosis 168: 195-211
7. von Eckardstein A et al. (2001) High density lipoproteins and arteriosclerosis: Role of cholesterol efflux and reverse cholesterol transport. Arterioscler Thromb Vasc Biol 21: 13-27
8. Kontush A et al. (2005) A normotriglyceridemic, low HDL-cholesterol phenotype is characterised by elevated oxidative stress and small, dense HDL particles with attenuated antioxidative activity. Atherosclerosis 182: 277-285
9. Nobecourt E et al. (2005) Defective antioxidative activity of small, dense HDL particles in type 2 diabetes: Relationship to elevated oxidative stress and hyperglycemia. Diabetologia 48: 529-538
10. Hansel B et al. (2004) Metabolic syndrome is associated with elevated oxidative stress and dysfunctional dense high-density lipoprotein particles displaying impaired antioxidative activity. J Clin Endocrinol Metab 89: 4963-4971
11. Morgan J et al. (2004) High-density lipoprotein subtractions and risk of coronary artery disease. Curr Atheroscler Rep 6: 359-365
12. Kontush A et al. (2003) Small, dense HDL particles exert potent protection of atherogenic LDL against oxidative stress. Arterioscler Thromb Vasc Biol 23: 1881-1888
13. Assmann G and Nofer JR (2003) Atheroprotective effects of high-density lipoproteins. Annu Rev Med 54: 321-341
14. Wang N et al. (2004) ATP-binding cassette transporters G1 and G4 mediate cellular cholesterol efflux to high-density lipoproteins. Proc Natl Acad Sci USA 101: 9774-9779
15. Ohta T et al. (1995) Different effects of subclasses of HDL containing apoA-I but not apoA-II (LpA-I) on cholesterol esterification in plasma and net cholesterol efflux from foam cells. Arterioscler Thromb Vasc Biol 15: 956-962
16. Sasahara T et al. (1998) Cholesterol transport between cells and high density lipoprotein subfractions from obese and lean subjects. J Lipid Res 39: 544-854
17. Asztalos B et al. (1997) Role of free apolipoprotein A-I in cholesterol efflux: Formation of pre-alpha-migrating high-density lipoprotein particles. Arterioscler Thromb Vasc Biol 17: 1630-1636
18. Navab M et al. (2004) The oxidation hypothesis of atherogenesis: The role of oxidized phospholipids and HDL. J Lipid Res 45: 993-1007
19. Marathe GK et al. (2003) Platelet-activating factor acetylhydrolase, and not paraoxonase-1, is the oxidized phospholipid hydrolase of high density lipoprotein particles. J Biol Chem 278: 3937-3947
20. Bowry VW et al. (1992) High density lipoprotein is the major carrier of lipid hydroperoxides in human blood plasma from fasting donors. Proc Natl Acad Sci USA 89: 10316-10320
21. Nicholls SJ et al. (2005) Reconstituted high-density lipoproteins inhibit the acute pro-oxidant and proinflammatory vascular changes induced by a periarterial collar in normocholesterolemic rabbits. Circulation 111: 1543-1550
22. Nofer JR and Assmann G (2005) Atheroprotective effects of high-density lipoprotein-associated lysosphingolipids. Trends Cardiovasc Med 15: 265-271
23. 2 expression in endothelial cells. Circulation 111: 2805-2811
24. Gomaraschi M et al. (2005) High-density lipoproteins attenuate interleukin-6 production in endothelial cells exposed to pro-inflammatory stimuli. Biochim Biophys Acta 1736: 136-143
25. Ashby DT et al. (1998) Factors influencing the ability of HDL to inhibit expression of vascular cell adhesion molecule-1 in endothelial cells. Arterioscler Thromb Vasc Biol 18: 1450-1455
26. Khovidhunkit W et al. (2004) Effects of infection and inflammation on lipid and lipoprotein metabolism: Mechanisms and consequences to the host. J Lipid Res 45: 1169-1196
27. Esteve E et al. (2005) Dyslipidemia and inflammation: An evolutionary conserved mechanism. Clin Nutr 24: 16-31
28. Malle E et al. (1993) Serum amyloid A (SAA): An acute phase protein and apolipoprotein. Atherosclerosis 102: 131-146
29. Ridker PM et al. (2000) C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med 342: 836-843
30. O'Brien KD et al. (2005) Serum amyloid A and lipoprotein retention in murine models of atherosclerosis. Arterioscler Thromb Vasc Biol 25: 785-790
31. Ansell BJ et al. (2003) Inflammatory/antiinflammatory properties of high-density lipoprotein distinguish patients from control subjects better than high-density lipoprotein cholesterol levels and are favorably affected by simvastatin treatment. Circulation 108: 2751-2756
32. Zheng L et al. (2004) Apolipoprotein A-I is a selective target for myeloperoxidase-catalyzed oxidation and functional impairment in subjects with cardiovascular disease. J Clin Invest 114: 529-541
33. Hedrick CC et al. (2000) Glycation impairs high-density lipoprotein function. Diabetologia 43: 312-320
34. Le Goff W et al. (2004) Pharmacological modulation of cholesteryl ester transfer protein, a new therapeutic target in atherogenic dyslipidemia. Pharmacol Ther 101: 17-38
35. Lamarche B et al. (1999) HDL metabolism in hypertriglyceridemic states: an overview. Clin Chim Acta 286: 145-161
36. Sparks DL et al. (1995) Effects of the neutral lipid content of high density lipoprotein on apolipoprotein A-I structure and particle stability. J Biol Chem 270: 26910-26917
37. Greene DJ et al. (2001) Elevated triglyceride content diminishes the capacity of high density lipoprotein to deliver cholesteryl esters via the scavenger receptor class B type I (SR-BI). J Biol Chem 276: 4804-4811
38. Cai L et al. (2005) Serum amyloid A is a ligand for scavenger receptor class B type I and inhibits high density lipoprotein binding and selective lipid uptake. J Biol Chem 280: 2954-2961
39. Artl A et al. (2000) Role of serum amyloid A during metabolism of acute-phase HDL by macrophages. Arterioscler Thromb Vasc Biol 20: 763-772
40. Curtiss LK et al. (2000) The conformation of apolipoprotein A-I in high-density lipoproteins is influenced by core lipid composition and particle size: A surface plasmon resonance study. Biochemistry 39: 5712-5721
41. 2α as a risk marker in patients with coronary heart disease: A matched case-control study. Circulation 109: 843-848
42. Finch CE and Crimmins EM (2004) Inflammatory exposure and historical changes in human life-spans. Science 305: 1736-1739
43. Clark RW et al. (2004) Raising high-density lipoprotein in humans through inhibition of cholesteryl ester transfer protein: An initial multidose study of torcetrapib. Arterioscler Thromb Vasc Biol 24: 490-497
44. Brousseau ME et al. (2004) Effects of an inhibitor of cholesteryl ester transfer protein on HDL cholesterol. N Engl J Med 350: 1505-1515
45. Kuivenhoven JA et al. (2005) Effectiveness of inhibition of cholesteryl ester transfer protein by JTT-705 in combination with pravastatin in type II dyslipidemia. Am J Cardiol 95: 1085-1088
46. Meyers CD et al. (2004) Niacin therapy in atherosclerosis. Curr Opin Lipidol 15: 659-665
47. Birjmohun RS et al. (2005) Efficacy and safety of high-density lipoprotein cholesterol-increasing compounds: A meta-analysis of randomized controlled trials. J Am Coll Cardiol 45: 185-197
48. Morgan JM et al. (2003) Effects of extended-release niacin on lipoprotein subclass distribution. Am J Cardiol 91: 1432-1436
49. Robins SJ et al. (2001) Relation of gemfibrozil treatment and lipid leAels with major coronary events: VA-HIT: a randomized controlled trial. JAMA 285: 1585-1591
50. Milano: Current perspectives. Curr Opin Lipidol 14: 159-163
51. Thompson MM et al. (2004) Therapeutic approaches to raising plasma HDL-cholesterol levels. Nature Clin Pract Cardiovas Med 1: 84-89
52. Nissen SE et al. (2003) Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: A randomized controlled trial. JAMA 290: 2292-2300
53. Nanjee MN et al. (1999) Acute effects of intravenous infusion of ApoA1/ phosphatidylcholine discs on plasma lipoproteins in humans. Arterioscler Thromb Vasc Biol 19: 979-989
54. Navab M et al. (2005) Apolipoprotein A-I mimetic peptides. Arterioscler Thromb Vasc Biol 25: 1325-1331
55. Navab M et al. (2004) Oral D-4F causes formation of pre-β high-density lipoprotein and improves high-density lipoprotein-mediated cholesterol efflux and reverse cholesterol transport from macrophages in apolipoprotein E-null mice. Circulation 109: 3215-3220
56. Brown BG et al. (2001) Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N Engl J Med 345: 1583-1592
57. Taylor AJ et al. (2004) Arterial biology for the investigation of the treatment effects of reducing cholesterol (ARBITER) 2: A double-blind, placebo-controlled study of extended-release niacin on atherosclerosis progression in secondary prevention patients treated with statins. Circulation 110: 3512-3517
58. Brousseau ME et al. (2005) Effects of cholesteryl ester transfer protein inhibition on high-density lipoprotein subspecies, apolipoprotein A-I metabolism, and fecal sterol excretion. Arterioscler Thromb Vasc Biol 25: 1057-1064
59. Navab M et al. (2005) D-4F and statins synergize to render HDL antiinflammatory in mice and monkeys and cause lesion regression in old apolipoprotein E-null mice. Arterioscler Thromb Vasc Biol 25: 1426-1432
60. Brewer HB Jr (2003) Benefit-risk assessment of rosuvastatin 10 to 40 milligrams. Am J Cardiol 92: 23K-29K